CHUGAI PHARMACEUTICAL CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public, Subsidiary

Established: 1925-03-10

Employees: 7.6K

Market Cap: $83.6B

Website: http://www.chugai-pharm.co.jp

Clinical Trials

Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)

Phase 3

Completed

Conditions: Predialysis Patients

Interventions: Drug: R744
Drug: Epoetin beta

First Posted Date: 2007-06-27

Last Posted Date: 2009-01-08

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 187

Registration Number: NCT00492427

Locations: 🇯🇵
Kanto/Koshinetsu region, Kanto/Koshinetsu, Japan
🇯🇵
Kyusyu region, Kyusyu, Japan
🇯🇵
Kinki/Hokuriku region, Kinki/Hokuriku, Japan

and more 3 locations

Clinical Study of R744 to Hemodialysis Patients

Phase 3

Completed

Conditions: Hemodialysis Patients

Interventions: Drug: R744
Drug: rHuEPO
Drug: R744 placebo
Drug: rHuEPO placebo

First Posted Date: 2007-06-26

Last Posted Date: 2009-02-02

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 134

Registration Number: NCT00491868

Locations: 🇯🇵
Kyusyu region, Kyusyu, Japan
🇯🇵
Chubu region, Chubu, Japan
🇯🇵
Kanto/Koshinetsu region, Kanto/Koshinetsu, Japan

and more 2 locations

Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: bevacizumab
Drug: Paclitaxel

First Posted Date: 2007-04-27

Last Posted Date: 2012-04-26

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 122

Registration Number: NCT00467012

Locations: 🇯🇵
Kyushu region, Kyushu, Japan
🇯🇵
Kanto Region, Kanto, Japan
🇯🇵
Kinki Region, Kinki, Japan

and more 2 locations

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis

Phase 3

Completed

Conditions: Primary Osteoporosis

Interventions: Drug: ibandronic acid placebo
Drug: ibandronic acid 0.5mg
Drug: RIS placebo
Drug: 1.0mg ibandronic acid
Drug: 2.5mg RIS
Dietary Supplement: Calcium and Vitamine D3

First Posted Date: 2007-03-15

Last Posted Date: 2012-08-02

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 1265

Registration Number: NCT00447915

Locations: 🇯🇵
Kanto/Koshinetsu region, Kanto/Koshinetsu, Japan
🇯🇵
Chubu/Kansai region, Chubu/Kansai, Japan
🇯🇵
Chugoku/Kyusyu region, Chugoku/Kyusyu, Japan

and more 1 locations

Clinical Study of R744 to Peritoneal Dialysis Patients

Phase 3

Completed

Conditions: Peritoneal Dialysis Patients

Interventions: Drug: R744

First Posted Date: 2007-02-12

Last Posted Date: 2009-02-02

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 72

Registration Number: NCT00433849

Locations: 🇯🇵
Kinki/Hokuriku region, Kinki/Hokuriku, Japan
🇯🇵
Chubu region, Chubu, Japan
🇯🇵
Chugoku/Shikoku region, Chugoku/Shikoku, Japan

and more 3 locations

Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)

Phase 3

Completed

Conditions: Hemodialysis Patients

Interventions: Drug: R744

First Posted Date: 2007-02-12

Last Posted Date: 2009-02-02

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 179

Registration Number: NCT00433888

Locations: 🇯🇵
Kinki/Hokuriku region, Kinki/Hokuriku, Japan
🇯🇵
Chubu region, Chubu, Japan
🇯🇵
Kanto/Koshinetsu region, Kanto/Koshinetsu, Japan

and more 3 locations

Clinical Study of R744 to Predialysis Patients

Phase 3

Completed

Conditions: Anemia in Pre-Dialysis Patients

Interventions: Drug: R744

First Posted Date: 2007-02-12

Last Posted Date: 2009-02-02

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 124

Registration Number: NCT00433615

Locations: 🇯🇵
Chubu region, Chubu, Japan
🇯🇵
Hokkaido/Tohoku region, Hokkaido/Tohoku, Japan
🇯🇵
Kanto/Koshinetsu region, Kanto/Koshinetsu, Japan

and more 3 locations

Correction Study of R744 in Renal Anemia Patients on Hemodialysis

Phase 3

Completed

Conditions: Hemodialysis Patients

Interventions: Drug: R744

First Posted Date: 2007-02-12

Last Posted Date: 2009-02-02

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 50

Registration Number: NCT00433693

Locations: 🇯🇵
Chugoku/Shikoku region, Chugoku/Shikoku, Japan
🇯🇵
Chubu region, Chubu, Japan
🇯🇵
Hokkaido/Tohoku region, Hokkaido/Tohoku, Japan

and more 3 locations

PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: MRA(Tocilizumab)

First Posted Date: 2006-09-26

Last Posted Date: 2009-12-23

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 20

Registration Number: NCT00380601

Locations: 🇯🇵
Hokuriku region, Hokuriku, Japan
🇯🇵
Kansai region, Kansai, Japan
🇯🇵
Kousinetsu region, Kousinetsu, Japan

and more 7 locations

Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2006-06-28

Last Posted Date: 2010-08-16

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 64

Registration Number: NCT00345761

Locations: 🇯🇵
Tokai Region, Tokai, Japan
🇯🇵
Hokkaido Region, Hokkaido, Japan
🇯🇵
Kanto Region, Kanto, Japan

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy